Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group.
Lange T, Niederwieser C, Gil A, Krahl R, von Grünhagen U, Al-Ali HK, Jentsch-Ullrich K, Spohn C, Lakner V, Assmann M, Junghanss C, Cross M, Hehlmann R, Deininger M, Pfirrmann M, Niederwieser D. Lange T, et al. Among authors: assmann m. Leuk Lymphoma. 2020 Dec;61(12):2821-2830. doi: 10.1080/10428194.2020.1786556. Epub 2020 Jul 16. Leuk Lymphoma. 2020. PMID: 32672489 Clinical Trial.
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
Koenigsmann M, Knauf W, Herold M, Pasold R, Müller G, Eschenburg H, Kahl C, Lakner V, Assmann M, Jentsch-Ullrich K, Mohren M, Bartsch R, Franke A. Koenigsmann M, et al. Among authors: assmann m. Leuk Lymphoma. 2004 Sep;45(9):1821-7. doi: 10.1080/1042819042000223822. Leuk Lymphoma. 2004. PMID: 15223642 Clinical Trial.
A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012.
Maschmeyer G, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D. Maschmeyer G, et al. Among authors: assmann m. J Cancer Res Clin Oncol. 2015 Sep;141(9):1639-44. doi: 10.1007/s00432-015-1954-x. Epub 2015 Mar 15. J Cancer Res Clin Oncol. 2015. PMID: 25773126
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).
Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D; East German Study Group of Hematology and Oncology (OSHO). Pönisch W, et al. Among authors: assmann m. J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12. doi: 10.1007/s00432-005-0074-4. Epub 2006 Jan 10. J Cancer Res Clin Oncol. 2006. PMID: 16402269 Clinical Trial.
Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.
Hirt C, Schüler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, Neser S, Assmann M, Srock S, Rohrberg R, Dachselt K, Leithäuser M, Rabkin CS, Herold M, Dölken G. Hirt C, et al. Among authors: assmann m. Br J Haematol. 2008 May;141(5):631-40. doi: 10.1111/j.1365-2141.2008.07101.x. Epub 2008 Apr 15. Br J Haematol. 2008. PMID: 18422779 Free article. Clinical Trial.
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Pönisch W, Bourgeois M, Moll B, Heyn S, Jäkel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, Aßmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schönfelder U, Zehrfeld T, Hensel G, Löschcke K, Krahl R, Ali HA, Niederwieser D. Pönisch W, et al. Among authors: assmann m. J Cancer Res Clin Oncol. 2013 Mar;139(3):499-508. doi: 10.1007/s00432-012-1339-3. Epub 2012 Nov 25. J Cancer Res Clin Oncol. 2013. PMID: 23184429
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U; East German Study Group Hematology and Oncology Study. Herold M, et al. Among authors: assmann m. J Clin Oncol. 2007 May 20;25(15):1986-92. doi: 10.1200/JCO.2006.06.4618. Epub 2007 Apr 9. J Clin Oncol. 2007. PMID: 17420513 Clinical Trial.
Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia.
Oelschlägel U, Nowak R, Schaub A, Köppel C, Herbst R, Mohr B, Löffler C, Range U, Günther H, Assmann M, Siegert E, Wendt E, Huhn R, Bräutigam E, Ehninger G. Oelschlägel U, et al. Among authors: assmann m. Cytometry. 2000 Aug 15;42(4):247-53. doi: 10.1002/1097-0320(20000815)42:4<247::aid-cyto5>3.0.co;2-v. Cytometry. 2000. PMID: 10934344 Free article.
Targeted Polariton Flow Through Tailored Photonic Defects.
Rozas E, Brune Y, West K, Baldwin KW, Pfeiffer LN, Beaumariage J, Alnatah H, Snoke DW, Aßmann M. Rozas E, et al. Among authors: assmann m. Nanomaterials (Basel). 2024 Oct 22;14(21):1691. doi: 10.3390/nano14211691. Nanomaterials (Basel). 2024. PMID: 39513771 Free PMC article.
85 results